New scenarios for cardiovascular prevention in Latin America in the framework of the COVID 19 pandemic

Since the first scientific communications regarding SAR-CoV2 infections in December 2019 in the city of Wuhan, China, the world agenda underwent unthinkable changes. In our country, compulsory preventive social isolation has become a favorable environment to sedentary lifestyle and inadequate nutrition, has increased the risk of psychological disorders related to depression and stress, and has facilitated the alteration of prescribed pharmacological schemes in chronic pathologies. Over the support of population strategies, specific actions will began to be developed for the particular subject. SRAA blockade is indicated in primary and secondary cardiovascular prevention, in prevention of target organ damage mediated by diabetes, or in heart failure. Although the advent of communications on the possible interactions between the putative ACE-2 receptor and the tissue distribution of SARS-CoV2 and cardiovascular risk, the absence of evidence supported in controlled clinical trials, and the impressive evidence with these drugs, had contributed that most scientific societies endorsed its therapeutic continuity. None of the drugs indicated for the treatment of coronary heart disease and secondary cardiovascular prevention, such as aspirin, beta-blockers, statins and nitrates, have been associated with worst results in the context of COVID-19 infection. The most important message is that patients with cardiovascular disease should continue to receive treatment and support from the health system. Telemedicine can be a suitable tool in these scenario.